

**Department:** Urology

Title of Presentation: Tumor Board

<u>Presenter (name/title):</u> Dr. Obi Ekwenna, M.D.

Dr. Firas Petros, M.D.

**Date of Activity:** April 23, 2025

**Start/Stop Time of Presentation:** 7:00-8:00am

**Location:** Webex

## <u>Target Audience:</u> Physicians, Residents, Nurses, Students and Ancillary Personnel

### **Learning Objectives:**

- 1. Review material for diagnosis and the appropriate methods for cancer treatment.
- 2. Describe rationale and indications for new diagnosis, treatment methods and the implications.
- 3. Discuss cancer related topics that will enhance detection, diagnosis, and management of patients with cancer.

#### **ACCREDITATION STATEMENT:**

The University of Toledo is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide medical education for physicians. The University of Toledo designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)* TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosures:** Available Online

Speakers: Dr. Obi Ekwenna, M.D.

Dr. Firas Petros, M.D.

#### Planning Committee Members: Dr. Obi Ekwenna, Dr. Firas Petros and Janelle Canard

Dr. Petros nor Janelle Canard have any financial interest or other relationship with a manufacturer of a commercial product or service to disclose.

Dr. Ekwenna discloses that he receives grant/research support from Natera.



# **UROLOGY TUMOR BOARD**

April 23, 2025 7:00 A.M. – 8:00 A.M. CME Meeting Code: 19070

Drs. Petros & Ekwenna – Co-Presenters

Patient Initials	MRN	Diagnosis	Attending	Questions for the Board	Research Study Candidate
DM	00270849	63 yoF w/ ccRCC AJCC stage III (pT3a, cN0, cM0). Review CT A/P 03/05/25, CT chest 03/17/25. Review path of right RNx 04/07/25 showing sinus fat invasion, metaplastic ossification in central area of sclerosis	FP		
ТВ	00903239	67yoM w/PCa, AJCC stage IIb (pT2, pN0, cM0, PSA 10.3 ng/mL, GG2). Review MRI prostate 05/08/24, FL cystogram 03/13/25, review Decipher report on prostate biopsy 06/28/24, path of RALP 02/27/25 showing Gleason pattern 4, and path of right bladder diverticulum (11.0 x 6.0 x 0.7 cm)	FP		
LD	00255371	62 yoF w/bilateral XGP, right perinephric abscess and empyema. Review CT C/A/P 1/26/25, MR renal mass 2/26/25. Review path of right RNx 4/3/25 showing XGP sclerotic and nonsclerotic pathologic changes	FP		



		1872		
MB	100111247	80yoM w/PCa, , AJCC stage IIb (cT1c, pN0, cM0, PSA 6.6 ng/mL (under finasteride effect, GG2). Review path of prostate biopsy 2/21/25, and report of ArteraAl Prostate Test 03/28/25	FP	
DA	00523997	62yoM w/PCa, AJCC stage IIa (cT2a, cN0, cM0, PSA 7.3 ng/mL, GG1 based on CCF). Review MRI prostate 11/19/24 and path of prostate biopsy 12/27/24 compared to MRI read and path read at CCF	FP	
PM	00870713	65yoM w/multiple comorbidties including ESRD s/p prior renal transplant, currently on HD w/possible left renal mass suspicious for renal neoplasm in setting of bilateral acquired renal cystic disease. Review CT renal mass protocol 03/15/25	FP	
BF	00968358	60 yo male with MIBC. Review outside CT A/P (if possible) from 3/23/2025. Review CT A/P and CT chest from 3/28/2025. Review pathology from TURBT on 3/25/2025. Patient has HFrEF with EF of 15-20%. Need to discuss treatment options as he is not ideal surgical candidate	OE	



MP	00111910	65 yo male with metastatic prostate cancer to mediastinal lymph node. Lymph node pathology showing overlapping small cell and acinar adenocarcinoma. Review CT chest from 1/13/2025 and CT A/P from 3/20/2025. Review cytology from	OE	
		from 1/13/2025 and CT A/P from 3/20/2025. Review cytology from 3/10/2025 and pathology from 3/22/2025		